Sugi Predict

Sugi Predict / Compounds / SCHEMBL296337

SCHEMBL296337

SCHEMBL296337

O=C(O)CCCC(=O)c1ccc(F)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.84
▸ RAB9A P51151 2/20 0.84
▸ HTR7 P34969 1/20 0.67
▸ PDE4B Q07343 1/20 0.61
▸ HDAC3 O15379 1/20 0.60
▸ HDAC4 P56524 1/20 0.60
▸ HDAC1 Q13547 1/20 0.60
▸ HDAC7 Q8WUI4 1/20 0.60
▸ HDAC2 Q92769 1/20 0.60
▸ HDAC10 Q969S8 1/20 0.60
▸ HDAC11 Q96DB2 1/20 0.60
▸ HDAC8 Q9BY41 1/20 0.60
▸ HDAC6 Q9UBN7 1/20 0.60
▸ HDAC9 Q9UKV0 1/20 0.60
▸ HDAC5 Q9UQL6 1/20 0.60
▸ KMT2A Q03164 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ PTPN1 P18031 1/20 0.53
▸ HSD11B1 P28845 1/20 0.51
▸ L3MBTL1 Q9Y468 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866967 0.96 NPC1 (0.77) NPC1RAB9AHTR7PDE4BHDAC3
SCHEMBL9953589 0.94 NPC1 (0.74) NPC1RAB9AHTR7PDE4BHDAC3
SCHEMBL28197598 0.88 NPC1 (0.84) NPC1RAB9AHTR7HDAC3HDAC4
SCHEMBL315309 0.88 RAB9A (0.69) NPC1RAB9AHTR7KMT2APTPN1
SCHEMBL9680520 0.87 NPC1 (0.91) NPC1RAB9AHTR7KMT2AMEN1
SCHEMBL3852844 0.86 NPC1 (0.88) NPC1RAB9AHTR7KMT2AMEN1
SCHEMBL1040636 0.85 NPC1 (0.87) NPC1RAB9AHTR7HDAC3HDAC4
SCHEMBL9680984 0.85 NPC1 (0.87) NPC1RAB9AHTR7HDAC3HDAC4
SCHEMBL3424496 0.85 NPC1 (0.87) NPC1RAB9AHTR7HDAC3HDAC4
SCHEMBL26584242 0.83 NPC1 (0.82) NPC1RAB9AHTR7KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119874759-A Ezetimibe Process for the preparation of intermediates 江苏阿尔法药业股份有限公司 2025-04-25 — — CN claimed
US-11884628-B2 Method for synthesizing lactam derivatives without use of catalyst GUIZHOU UNIVERSITY (CN) 2024-01-30 — — US claimed
US-20220177429-A1 METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST GUIZHOU UNIVERSITY (CN) 2022-06-09 — — US claimed
CN-112778117-A Method for synthesizing 4- (4-fluorobenzoyl) butyric acid and analogue thereof in continuous flow microreactor 江苏阿尔法药业有限公司 2021-05-11 — — CN claimed
WO-2020228170-A1 CATALYST-FREE SYNTHESIS METHOD FOR LACTAM DERIVATIVE 贵州大学 2020-11-19 — — WO claimed
CN-109942473-B Method for synthesizing lactam derivative without catalyst 贵州大学 2020-09-15 — — CN claimed
CN-111138276-A Synthesis method of chiral 5- (4-fluorophenyl) -5-hydroxypentanoate 郑州手性药物研究院有限公司 2020-05-12 — — CN claimed
CN-109942473-A A kind of method of catalyst-free synthesis lactam derivatives 贵州大学 2019-06-28 — — CN claimed
CN-106397292-A Ezetimibe intermediate, synthesis method of intermediate and synthesis method of ezetimibe 苏州普罗达生物科技有限公司 2017-02-15 — — CN claimed
CN-103849574-B Candida parapsilosis ZJPH1305 and the application in chiral alcohol preparation JIANG University OF TECHNOLOGY (CN) 2016-03-02 — — CN claimed
EP-2004639-A2 PROCESSES FOR THE SYNTHESIS OF AZETIDINONE Teva Pharmaceutical Industries Ltd (IL) 2008-12-24 — — EP claimed
US-20080032964-A1 Process for the synthesis of azetidinone TEVA PHARMACEUTICALS USA, INC. 2008-02-07 — — US claimed
WO-2007120824-A2 PROCESSES FOR THE SYNTHESIS OF AZETIDINONE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-10-25 — — WO claimed
EP-1831162-A1 PROCESS FOR THE SYNTHESIS OF AZETIDINONES SCHERING CORPORATION (US) 2007-09-12 — — EP claimed
WO-2006068990-A1 PROCESS FOR THE SYNTHESIS OF AZETIDINONES SCHERING CORPORATION (US) 2006-06-29 — — WO claimed
US-20060135755-A1 Process for the synthesis of azetidinones SCHERING CORPORATION 2006-06-22 — — US claimed
EP-1137634-B1 PROCESS FOR THE SYNTHESIS OF AZETIDINONES SCHERING CORP (US) 2005-06-15 — — EP claimed
EP-1137634-A1 PROCESS FOR THE SYNTHESIS OF AZETIDINONES SCHERING CORPORATION (US) 2001-10-04 — — EP claimed
US-6207822-B1 REACTING P-FLUOROBENZOYLBUTYRIC ACID WITH PIVALOYL CHLORIDE;ACYLATION; REDUCTION; CYCLIZATION; HYDROSILATION; DEBLOCKING SCHERING CORPORATION 2001-03-27 — — US claimed
WO-2000034240-A1 PROCESS FOR THE SYNTHESIS OF AZETIDINONES SCHERING CORPORATION (US) 2000-06-15 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032964-A1 Process for the synthesis of azetidinone CYP46A1, APOB, CYP51A1 NPC1 108/4885RAB9A 1409/4885HTR7 1119/4885
US-11884628-B2 Method for synthesizing lactam derivatives without use of catalyst COASY, SI, NAAA NPC1 4156/4885RAB9A 1712/4885HTR7 3829/4885
US-20220177429-A1 METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST COASY, SI, NAAA NPC1 4156/4885RAB9A 1712/4885HTR7 3829/4885
US-20060135755-A1 Process for the synthesis of azetidinones LSS, ASNS, CYP51A1 NPC1 138/4885RAB9A 2218/4885HTR7 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.